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IMPORTANCE ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer
(mBC) and gastric cancer, but additional treatments are needed to maximize efficacy and
quality of life.
OBJECTIVE To determine maximum tolerated doses (MTDs) of trastuzumab emtansine
(T-DM1) plus capecitabine in patients with previously treated ERBB2-positive mBC and locally
advanced/metastatic gastric cancer (LA/mGC) (phase 1) and the efficacy and safety of this
combination vs T-DM1 alone in patients with mBC (phase 2).
DESIGN, SETTING, AND PARTICIPANTS The MTD in phase 1 was assessed using a 3 + 3 design
with capecitabine dose modification. Phase 2 was an open-label, randomized, international
multicenter study of patients with mBC treated with T-DM1 plus capecitabine or T-DM1 alone.
Eligible patients had previously treated ERBB2-positive mBC or LA/mGC with no prior
chemotherapy treatment for advanced disease.
INTERVENTIONS Patients in the phase 1 mBC cohort received capecitabine (750 mg/m2, 700
mg/m2, or 650 mg/m2 twice daily, days 1-14 of a 3-week cycle) plus T-DM1 3.6 mg/kg every 3
weeks. Patients with LA/mGC received capecitabine at the mBC phase 1 MTD, de-escalating
as needed, plus T-DM1 2.4 mg/kg weekly. In phase 2, patients with mBC were randomized (1:1)
to receive capecitabine (at the phase 1 MTD) plus T-DM1 or T-DM1 alone.
MAIN OUTCOMES AND MEASURES The phase 1 primary objective was to identify the MTD of
capecitabine plus T-DM1. The phase 2 primary outcome was investigator-assessed overall
response rate (ORR).
RESULTS In phase 1, the median (range) age was 54.0 (37-71) and 57.5 (53-70) years for
patients with mBC and patients with LA/mGC, respectively. The capecitabine MTD was
identified as 700 mg/m2 in 11 patients with mBC and 6 patients with LA/mGC evaluable for
dose-limiting toxic effects. In phase 2, between October 2014 and April 2016, patients with
mBC (median [range] age, 52.0 [28-80] years) were randomized to receive combination
therapy (n = 81) or T-DM1 (n = 80). The ORR was 44% (36 of 81 patients) and 36% (29 of 80
patients) in the combination and T-DM1 groups, respectively (difference, 8.2%; 90% CI, −4.5
to 20.9; P = .34; clinical cutoff, May 31, 2017). Adverse events (AEs) were reported in 78 of 82
patients (95%) in the combination group, with 36 (44%) experiencing grade 3-4 AEs, and 69
of 78 patients (88%) in the T-DM1 group, with 32 (41%) experiencing grade 3-4 AEs. No grade
5 AEs were reported.
CONCLUSIONS AND RELEVANCE Adding capecitabine to T-DM1 did not statistically increase
ORR associated with T-DM1 in patients with previously treated ERBB2-positive mBC. The
combination group reported more AEs, but with no unexpected toxic effects.
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O verexpression of ERBB2 (formerly HER2) is associ-ated with poor clinical outcomes in patients withsolid tumors.1,2 Therapies targeted at ERBB2, such as
trastuzumab, have significantly improved outcomes for pa-
tients with ERBB2-positive metastatic breast cancer (mBC) and
metastatic gastric cancer (mGC).3-9 However, prognoses for
patients with mBC or mGC remain poor, and additional treat-
ments are needed.
Trastuzumab emtansine (T-DM1) is an antibody-drug con-
jugate combining trastuzumab and the cytotoxic microtubule-
inhibitor DM1.10 In the phase 3 EMILIA study of patients
with previously treated ERBB2-positive advanced breast
cancer, T-DM1 conferred significantly longer progression-
free survival (PFS) and overall survival (OS) vs lapatinib plus
capecitabine,8 leading to the US approval of single-agent T-DM1
in this setting. T-DM1 was also investigated in patients with pre-
viously treated ERBB2-positive locally advanced (LA)/mGC or
gastroesophageal junction cancer in the phase 2/3 GATSBY
study, which found that T-DM1 alone was not superior to a
taxane.11
Combination trastuzumab plus capecitabine has shown
clinical activity in patients with previously treated ERBB2-
positive mBC.12-14 Trastuzumab plus chemotherapy, includ-
ing capecitabine, is the first-line standard-of-care treatment
for ERBB2-positive advanced gastric cancer.6 In the phase 3
ToGA trial of patients with ERBB2-positive advanced gastric
cancer, first-line trastuzumab plus chemotherapy (capecitabine
plus cisplatin or fluorouracil plus cisplatin) improved OS and
PFS vs chemotherapy alone, without substantially affecting
safety.15
These studies, along with preclinical evidence showing
additive activity when combining T-DM1 with chemothera-
peutic agents,16 suggest that capecitabine plus T-DM1 may dem-
onstrate efficacy in the treatment of mBC and LA/mGC. We con-
ducted the TRAXHER2 trial (NCT01702558) to determine the
maximum tolerated doses (MTDs) of T-DM1 plus capecitabine
in ERBB2-positive mBC and LA/mGC and to explore efficacy
of this combination vs T-DM1 monotherapy in patients with
previously treated ERBB2-positive mBC.
Methods
Study Design and Patients
TRAXHER2 was a phase 1/2 study (trial protocol in Supple-
ment 1; eFigure 1 in Supplement 2). Phase 1 assessed MTDs of
capecitabine in combination with T-DM1 in patients with
ERBB2-positive mBC (cohort 1) or LA/mGC (cohort 2) using a
3 + 3 classical study design with dose modification for ca-
pecitabine. Phase 2 was an international, open-label, random-
ized study of efficacy and safety of this combination in patients
with ERBB2-positive mBC.
All patients were 18 years or older and had ERBB2-
positive tumors, Eastern Cooperative Oncology Group (ECOG)
performance status of 2 or lower, adequate liver/renal func-
tion, left ventricular ejection fraction of 50% or greater, and
life expectancy of 12 weeks or longer. Patients with mBC had
at least 1 prior treatment for early or metastatic disease (in-
cluding trastuzumab and chemotherapy, separately or in com-
bination); those with LA/mGC had no prior chemotherapy for
advanced disease. Additional inclusion and exclusion criteria
are detailed in the eMethods in Supplement 2.
The TRAXHER2 study was conducted per the Interna-
tional Conference on Harmonization Good Clinical Practice
standards and the Declaration of Helsinki. The study proto-
col was approved by the institutional review boards or ethics
committees of participating institutions. All patients pro-
vided written informed consent. Patients were not paid for
participating in the study; payments to patients for travel
expenses and small refreshments were covered per local
regulations.
Procedures
The phase 1 mBC cohort established the MTD, which was used
as the starting capecitabine dose for the phase 1 LA/mGC co-
hort and as the recommended phase 2 dose (RP2D) for the com-
bination arm. Although the phase 1 mBC cohort was initially
designated as a dose-escalation study, because of dose-
limiting toxic effects (DLTs) observed at dose level 1 in 2 pa-
tients, the study design was adapted for de-escalation. Three
possible capecitabine dose levels were thus evaluated in the
mBC cohort: 750 mg/m2 (dose level 1), 700 mg/m2 (dose level
−1), and 650 mg/m2 (dose level −2) (eFigure 1 in Supple-
ment 2). Capecitabine was given twice daily (days 1-14 of a
3-week cycle) plus T-DM1 3.6 mg/kg every 3 weeks.
Patients in the phase 1 LA/mGC cohort were also treated
using a de-escalation design, starting with the capecitabine
MTD from the phase 1 mBC cohort (700 mg/m2; dose level −1)
(eFigure 1 in Supplement 2). Capecitabine was given twice
daily (days 1-14 of a 3-week cycle) plus T-DM1 2.4 mg/kg
weekly. Additional details are included in the eMethods in
Supplement 2.
In phase 2, patients with mBC were randomized 1:1 to
T-DM1 plus capecitabine (at phase 1 MTD) or T-DM1 alone
(3.6 mg/kg every 3 weeks). Treatment continued until dis-
ease progression, unacceptable toxic effects, patient with-
drawal, death, or at the discretion of the treating physician
(eTable 1 in Supplement 2).
Key Points
Question What is the effect of adding capecitabine to
trastuzumab emtansine (T-DM1) treatment in patients with
previously treated ERBB2 (HER2)-positive metastatic breast
cancer?
Findings In this phase 1/2 randomized clinical trial of 161 patients
with previously treated ERBB2-positive metastatic breast cancer,
the overall response rate was 44% and 36% in the combination
and single-agent T-DM1 arms, respectively; median overall survival
was not estimable and 24.7 months. Adverse events occurred in
95% (grade 3-4: 44%) and 89% (grade 3-4: 41%) of patients in
each arm, respectively.
Meaning Adding capecitabine to T-DM1 increases toxic effects
and does not improve clinical outcomes vs T-DM1 alone for
previously treated ERBB2-positive metastatic breast cancer.
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Tumors were assessed for response at 9 weeks and then
every 12 weeks until progressive disease or study termina-
tion. Adverse events (AEs) were coded using the National Can-
cer Institute’s Common Terminology Criteria for Adverse
Events, version 4.0. Additional procedural methods are in-
cluded in the eMethods and eTable 1 in Supplement 2.
Outcomes
The phase 1 primary outcome was the MTD for T-DM1 plus ca-
pecitabine in mBC and LA/mGC. The secondary outcome was
overall response rate (ORR) based on the best overall re-
sponse per investigator-assessed Response Evaluation Crite-
ria in Solid Tumors (RECIST), version 1.1 (unconfirmed).
The phase 2 primary outcome was investigator-assessed
ORR using RECIST, version 1.1, with complete/partial re-
sponses (CR/PR) or stable disease (SD; ≥6-week duration from
randomization) confirmed at a subsequent visit. Secondary end
points were safety, PFS, OS, clinical benefit rate (confirmed
CR/PR or SD≥6 months), time to response, duration of re-
sponse, time to progression, and time to treatment failure. The
ORR by ERBB2 subgroup was an exploratory end point.
Statistical Analysis
Phase 1 sample sizes were based on a classical 3 + 3 design with
enrollment of 6 to 18 patients with mBC and 3 to 12 patients
with LA/mGC. Phase 2 sample size was based on a Fisher ex-
act test with an α level of 5% (1-sided) and power of 70%, and
the clinical assumption of ORRs of 62.5% for T-DM1 plus ca-
pecitabine and 43% for T-DM1 alone. Based on these assump-
tions and a 15% withdrawal rate, approximately 160 patients
(80 patients per group) were to be randomized.
The primary analysis of phase 2 was prespecified to oc-
cur when 70% of patients had experienced a PFS event. This
clinical cutoff was applied on May 31, 2017, 31 months after first
patient randomization, at which point the last patient ran-
domized (April 26, 2016) could be adequately evaluated for best
overall response. This allowed for calculation of the primary
end point (ORR) and estimation of median PFS using the
Kaplan-Meier method. This analysis represents final results
from the TRAXHER2 study. Statistical analyses were per-
formed using SAS, version 9 (SAS Institute).
Results
Patients
Baseline demographic and disease characteristics for all pa-
tients are summarized in eTable 2 in Supplement 2. In phase
1, 12 patients were enrolled in the mBC cohort, 11 of whom were
evaluable for DLTs; the excluded patient did not meet eligi-
bility criteria for liver enzyme stability. Six patients were en-
rolled in the LA/mGC cohort and evaluable for DLTs. In phase
2, between October 17, 2014, and April 29, 2016, 161 patients
with ERBB2-positive mBC (median [range] age, 52.0 [28-80]
years) were randomized to receive T-DM1 plus capecitabine
(n = 81) or T-DM1 alone (n = 80) (Figure 1). In phase 2, patient
and disease characteristics were well balanced between treat-
ment arms and comparable to patients in phase 1. Most were
white women with an ECOG performance status of 1 or lower,
had visceral disease, and had 1 or fewer prior lines of mBC treat-
ment. Of 6 patients in the phase 1 LA/mGC cohort, 3 (50%) had
adenocarcinoma of the gastroesophageal junction. All 6 pa-
tients were white men with an ECOG performance status of 1
or lower.
Phase 1
Of 11 DLT-evaluable patients in the mBC cohort, 6 were treated
at dose level 1 and 5 were treated at dose level −1. Two of 6 pa-
tients receiving dose level 1 experienced DLTs: one had grade
3 elevated alanine aminotransferase and aspartate amino-
transferase levels, while the other had grade 3 vomiting and
grade 1 nausea. None of the patients receiving dose level −1 had
a DLT; therefore, the MTD and RP2D for mBC was identified
as capecitabine 700 mg/m2 twice daily (days 1-14 of a 3-week
Figure 1. Patient Disposition in Phase 2
161 Patients enrolled
47 Discontinued the study
16 Died
16 Discontinued for other reasons
12 Withdrew consent
3 Were lost to follow-up
42 Discontinued the study
20 Died
17 Discontinued for other reasons
4 Withdrew consent
1 Discontinued because of trial
termination by sponsor
161 Randomized
81 Randomized to T-DM1 + capecitabine
(ITT population)
80 Randomized to T-DM1 alone
(ITT population)
82 Treated with T-DM1 + capecitabine
(safety population)a
78 Treated with T-DM1 alone
(safety population)a,b
34 Completed the studyc 38 Completed the studyc
a One patient randomized to the
T-DM1 alone group also received
capecitabine throughout the study
and is included in the
T-DM1 + capecitabine safety
population.
b One patient in the T-DM1 alone
group was randomized in error and
was not treated.
c Patients who completed the study
were those patients in follow-up
who had their last visit within the
last 6 months prior to the clinical
cutoff date (May 31, 2017).
ITT indicates intention-to-treat;
T-DM1, trastuzumab emtansine.
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cycle) plus T-DM1 3.6 mg/kg every 3 weeks. In the LA/mGC co-
hort, all 6 patients were treated at dose level −1; none experi-
enced a DLT. Therefore, the MTD was capecitabine 700 mg/m2
twice daily (days 1-14 of a 3-week cycle) plus T-DM1 2.4 mg/kg
weekly.
Median (interquartile range [IQR]) overall study drug ex-
posure was 14.3 (7.7-25.3) months and 4.0 (2.6-7.4) months in
the mBC and LA/mGC cohorts, respectively. Among 11 DLT-
evaluable patients with mBC, 10 had unconfirmed PR (5 each
at dose levels 1 and −1). In the LA/mGC cohort, 5 patients had
an unconfirmed CR (n = 1) or PR (n = 4).
Phase 2
At the clinical cutoff, median (IQR) study drug exposure was
7.6 (4.1-13.8) months. The ORR was 44% (36 of 81) in the com-
bination arm and 36% (29 of 80) in the T-DM1 arm (differ-
ence, 8.2%; 90% CI, −4.5 to 20.9; P = .34). Median PFS was 10.2
months (90% CI, 7.9-12.6) for the combination arm and 9.8
months (90% CI, 7.5-13.1) for the T-DM1 arm (stratified haz-
ard ratio, 0.92; 90% CI, 0.67-1.25) (Figure 2). Median OS was
not estimable (NE; 90% CI, NE-NE) for the combination arm
and 24.7 months (90% CI, 24.3-NE) for the T-DM1 arm (strati-
fied hazard ratio, 0.87; 90% CI, 0.51-1.48) (eFigure 2 in Supple-
ment 2). Consistent results were seen for the other secondary
efficacy end points (Table). In the exploratory analysis, ORR
results were consistent within ERBB2 subgroups defined by
immunohistochemistry level (eTable 3 in Supplement 2).
In the combination and T-DM1 arms, 9 and 7 patients, re-
spectively, had brain lesions at screening. In the combination
arm, 2 patients had CR, 3 had PR, 2 had SD, and 2 had progres-
sive disease. In the T-DM1 arm, 6 patients had SD in the brain
and 1 had progressive disease. In the combination and T-DM1
arms, 1 and 6 patients, respectively, developed new brain le-
sions during the study.
The safety population included 82 patients in the combi-
nation arm and 78 in the T-DM1 arm (Figure 1). Two patients
randomized to receive T-DM1 were not included in the safety
population for this treatment arm: one received capecitabine
and is included in the combination arm for the safety analy-
sis; the other was randomized in error and was not treated.
Study termination was most commonly owing to death in
both treatment arms (combination arm, 16 of 47 patients [34%];
T-DM1 arm, 20 of 42 patients [48%]; eTable 4 in Supplement 2).
Treatment discontinuation was most commonly due to disease
progression; in the combination arm (n = 81), 49 of 81 patients
(61%) discontinued T-DM1 and 44 (54%) discontinued ca-
pecitabine with disease progression as the primary reason. In the
T-DM1 arm (n = 80), disease progression was the primary rea-
son for discontinuation of T-DM1 in 48 patients (60%). Other rea-
sons for study/treatment discontinuation are presented in
eTable 4 in Supplement 2.
Median (IQR) duration of T-DM1 exposure was 7.7 (3.5-
13.4) months and 7.6 (4.2-14.5) months in the combination and
T-DM1 arms, respectively. Median (IQR) duration of ca-
pecitabine exposure was 6.4 (3.7-12.8) months. Overall, 27 of
82 patients (33%) and 29 of 78 patients (37%) in the combina-
tion and T-DM1 arms, respectively, had a reduction in T-DM1
dose; 44 (54%) and 44 (56%) patients, respectively, had a T-DM1
Figure 2. Progression-Free Survival in Patients With Metastatic


























































































55 59No. of events
10.2 9.8Median PFS, mo
0.92 (0.67 to 1.25)Stratified HR (90% CI) 
Patients without progression/death were censored at the date of the last tumor
assessment. HR estimates and 90% CIs are from a Cox regression model
stratified by the number of previous lines of treatment.
HR indicates hazard ratio; T-DM1, trastuzumab emtansine.
Table. Efficacy Results From Phase 2
T-DM1 + capecitabine
(n = 81) T-DM1 (n = 80)
Overall response
rate, No. (%) [90%
CI]
36 (44.4) [35.0 to 54.2] 29 (36.3) [27.3 to 46.0]
Difference, %
(90% CI)
8.2 (−4.5 to 20.9)
P value .34
Clinical benefit rate,
No. (%) [90% CI]





2 (2) 2 (3)
Partial response 34 (42) 27 (34)
Stable disease 24 (30) 26 (33)
Progressive
disease
14 (17) 23 (29)
Not evaluable 7 (9) 2 (3)
Time to response,
median (IQR), moa








9.86 (4.67 to 15.87) 7.66 (4.27 to 14.52)
Time to progression,
median (IQR), mo
10.38 (4.93 to NE) 10.32 (4.83 to 18.43)
Abbreviations: IQR, interquartile range; NE, not estimable; T-DM1, trastuzumab
emtansine.
a Provided for responders only.
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dose delay. At last patient visit, 26 patients were still on treat-
ment in phase 2 (14 in the combination arm; 12 in the T-DM1
arm), and 1 patient was still on combination treatment from
phase 1 (mBC cohort; dose level −1).
Adverse events were reported by 78 of 82 (95%) and 69 of
78 (88%) patients in the combination and T-DM1 treatment
arms, respectively, and grade 3-4 AEs were reported in 36 (44%)
and 32 (41%) patients (eTable 5 in Supplement 2). No grade 5
AEs or unexpected safety issues were observed. The 3 most
frequently occurring grade 3-4 AEs were thrombocytopenia
(combination, 8 patients [10%]; vs T-DM1, 3 patients [4%]), in-
creased AST (4 [5%] vs 5 [6%]), and increased γ-glutamyltrans-
ferase (4 [5%] vs 5 [6%]) (eTable 5 in Supplement 2). Three
patients in each arm experienced grade 4 AEs, including
thrombocytopenia, brain edema, and pulmonary embolism
(combination arm), and thrombocytopenia, hepatocellular
injury, and bacterial sepsis (T-DM1 arm). Study and/or treat-
ment discontinuation owing to AEs was higher in the combi-
nation vs the T-DM1 arm (23 of 82 patients [28%] vs 12 of 78
patients [15%]). Adverse events leading to study/treatment
discontinuation in 2% or greater of patients (regardless of
treatment) were thrombocytopenia (combination, 5 [6%]; vs
T-DM1, 3 [4%]), increased blood bilirubin (2 [2%] vs 2 [3%]),
and decreased platelet count (2 [2%] vs 1 [1%]) (eTable 6 in
Supplement 2).
Discussion
In phase 1, the MTD for mBC was capecitabine 700 mg/m2 twice
daily (days 1-14 of a 3-week cycle) plus T-DM1 3.6 mg/kg every
3 weeks, which established the RP2D. For LA/mGC, the MTD was
capecitabine 700 mg/m2 twice daily (days 1-14 of a 3-week cycle)
plus T-DM1 2.4 mg/kg weekly. Unconfirmed responses were ob-
served in both cohorts, including 1 CR (LA/mGC cohort). In phase
2, the addition of capecitabine to T-DM1 did not statistically in-
crease the ORR vs T-DM1 alone in patients with previously
treated ERBB2-positive mBC (ORRs, 44% and 36% in the com-
bination and T-DM1 monotherapy groups, respectively). The
T-DM1 safety profile was generally consistent with previous re-
ports of T-DM1 use in this setting8,9,17-19; however, among AEs
occurring in 15% or greater of either treatment arm, incidences
of thrombocytopenia, palmar-plantar erythrodysesthesia, vom-
iting, nausea, epistaxis, and neutropenia were higher (≥5% dif-
ference) in the combination arm vs the T-DM1 arm. In addi-
tion, more patients in the combination arm discontinued
treatment because of AEs. No grade 5 AEs or unexpected safety
issues were observed in either treatment arm.
When TRAXHER2 was designed, we hypothesized that
combining T-DM1 with capecitabine might improve efficacy
inpatientswithpreviouslytreatedmBC.Findingsfromthepres-
ent study did not support this hypothesis. Two other trials have
also investigated T-DM1 combined with chemotherapeutic
agents in patients with ERBB2-positive advanced breast
cancer.20,21 In study BP22572, T-DM1 plus docetaxel treatment
resulted in an ORR of 80% (20 CRs/PRs of 25 treated patients).20
However, 12 patients (48%) required dose modifications ow-
ing to AEs, and higher severe/serious AE rates were observed
relative to prior studies with single-agent T-DM1. In study
TDM4652g, heavily pretreated patients received T-DM1 plus pa-
clitaxel with or without pertuzumab; ORR was 50% (n = 21) in
42 patients (48% with T-DM1 plus paclitaxel and 52% with T-DM1
plus paclitaxel and pertuzumab).21 High rates of peripheral
neuropathy led to the conclusion that it was unclear whether
adding pertuzumab or paclitaxel enhanced clinical activity of
single-agent T-DM1. These trials suggest either no or a modest
improvement in efficacy when chemotherapy is added to T-DM1,
with an increase in toxic effects. Similarly, we observed no im-
provement in efficacy from the addition of capecitabine to
T-DM1 in TRAXHER2. Further studies may provide additional
data, including a phase 1 study of T-DM1 plus nonpegylated li-
posomal doxorubicin (MEDOPP038; THELMA).22 Other stud-
ies are investigating targeted therapy combinations, including
T-DM1 plus tyrosine kinase inhibitors.
Limitations
Our study was limited by several factors, including the small
number of patients. In addition, as phase 1 responses were un-
confirmed, these efficacy results should be interpreted with
caution, especially when compared with confirmed response
data from phase 2. Short follow-up duration also limits our abil-
ity to characterize potential long-lasting benefits in respond-
ing patients. Furthermore, while T-DM1 plus capecitabine could
be hypothesized to provide enhanced benefit in the setting
of ERBB2 expression heterogeneity, the level of ERBB2
heterogeneity in patients with mBC or LA/mGC included in
TRAXHER2 is unknown. Finally, while 2 CRs and 3 PRs were
observed among 9 patients with baseline brain lesions in the
combination arm, it is not possible to draw conclusions about
T-DM1 plus capecitabine efficacy in this population because
of the small patient numbers.
Conclusions
The MTD for capecitabine, in combination with T-DM1, was
identified as 700 mg/m2 in both the mBC and LA/mGC phase
1 cohorts. In phase 2, the addition of capecitabine to T-DM1 did
not statistically increase the ORR associated with T-DM1 alone
in previously treated ERBB2-positive mBC, although it is pos-
sible that different dose combinations or schedules may im-
prove outcomes.
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